Raised CRP levels mark metabolic and functional impairment in advanced COPD

Thorax

Volumn 61, Issue 1, 2006, Pages 17-22

  Broekhuizen, R ^a   Wouters, E F M ^a   Creutzberg, E C ^b   Schols, A M W J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Asthma Centre Hornerheide   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; INTERLEUKIN 6; IPRATROPIUM BROMIDE; THEOPHYLLINE;

ADULT; AGE; AGED; ARTICLE; BICYCLE ERGOMETRY; BODY COMPOSITION; BODY FAT; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISABILITY; DISEASE MARKER; ENERGY EXPENDITURE; ENERGY METABOLISM; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL DISEASE; HEALTH STATUS; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; REGRESSION ANALYSIS; SEX DIFFERENCE; SYMPTOM; WALKING;

BODY MASS INDEX; C-REACTIVE PROTEIN; ENERGY METABOLISM; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; MUSCLE WEAKNESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 30844447198     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.041996     Document Type: Article

References (39)

1. ATS/ERS. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999;159:51-40.
2. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80.
3. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from tfie Third National Health and Nutrition Examination. Am J Med 2003;114:758-02.
4. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:577-121.
5. Quanjer PH. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J 1993;6(Suppl 16):1-100.
6. Steiner MC, Barton RL, Singh SJ, et al. Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J 2002;19:626-31.
7. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. Nutrition 1990;6:213-21.
8. Leeuwenberg JF, Jeunhomme TM, Buurman WA. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 1994;152:4036-43.
9. Gaesser GA, Brooks GA. Muscular efficiency during steady-rate exercise: effects of speed and work rate. J Appl Physiol 1975;38:1132-9.
10. Baarends EM, Schols AM, Akkermans MA, et al. Decreased mechanical efficiency in clinically stable patients with COPD. Thorax 1997;52:981-6.
11. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
12. Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995;107(5Suppl):187-93S.
13. Cirillo DJ, Agrawal Y, Cassano PA. Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002;155:842-8.
14. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-90.
15. Dentener MA, Creutzberg EC, Schols AM, et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001;56:721-6.
16. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.
17. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
18. Vemooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;106:1218-24.
19. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004;23:685-91.
20. Keller C, Steensberg A, Pilegaard H, et al. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 2001;15:2748-50.
21. Pedersen BK, Steensberg A, Fischer C, et al. The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor? Proc Nutr Soc 2004;63:263-7.
22. Kosmidou I, Vassilakopoulos T, Xagorari A, et al. Production of interleukin-6 by skeletal myotubes: role of reactive oxygen species. Am J Respir Cell Mol Biol 2002;26:587-93.
23. Fischer CP, Hiscock NJ, Penkowa M, et al. Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol 2004;558:633-45.
24. Maltais F, LeBlanc P, Whittom F, et al. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax 2000;55:848-53.
25. Engelen MP, Schols AM, Does JD, et al. Exercise-induced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1697-704.
26. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. Eur Respir J 1990;3:192-6.
27. Maltais F, Simard AA, Simara C, et al. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 1996;153:288-93.
28. Koechlin C, Couillard A, Cristol JP, et al. Does systemic inflammation trigger local exercise-induced oxidative stress in COPD? Eur Respir J 2004;23:538-44.
29. Rabinovich RA, Ardite E, Troosters T, et al. Reduced muscle redox capacity after endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1114-8.
30. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
31. Geffken DF, Cushman M, Burke GL, et al. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 2001;153:242-50.
32. Reeds PJ, Fjeld CR, Jahoor F. Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states? J Nutr 1994;124:906-10.
33. Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-5.
34. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
35. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
36. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
37. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003;22:809-14.
38. Dev D, Wallace E, Sankaran R, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998;92:664-7.
39. Cano NJ, Richard C, Roth H, et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004;126:540-6.